Revive Therapeutics Ltd
31R
Company Profile
Business description
Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care. The company is exploring the use of Bucillamine for the potential treatment of public health medical emergencies and rare inflammatory disorders. Revive is also advancing the development of Psilocybin-based therapeutics through various programs.
Contact
82 Richmond Street East
The Canadian Venture Building
TorontoONM5C 1P1
CANT: +1 888 901-0036
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
30 June 2027
Employees
3
Stocks News & Analysis
stocks
The strange effect of the 30% minimum capital gains tax
How the proposed CGT floor creates unexpected outcomes across different incomes.
stocks
Major ASX miner reduces aluminium exposure
The Alcoa transaction unlocks value and sharpens ASX miners focus on base metals.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,004.70 | 38.80 | -0.43% |
| CAC 40 | 8,436.24 | 43.63 | -0.51% |
| DAX 40 | 25,465.25 | 352.64 | -1.37% |
| Dow JONES (US) | 52,925.15 | 130.76 | -0.25% |
| FTSE 100 | 10,665.88 | 14.11 | 0.13% |
| HKSE | 23,496.89 | 119.43 | -0.51% |
| NASDAQ | 25,818.69 | 302.47 | -1.16% |
| Nikkei 225 | 68,256.96 | 1,480.73 | -2.12% |
| NZX 50 Index | 13,710.76 | 52.03 | -0.38% |
| S&P 500 | 7,503.85 | 33.58 | -0.45% |
| S&P/ASX 200 | 8,803.90 | 35.50 | -0.40% |
| SSE Composite Index | 3,990.24 | 51.00 | -1.26% |